A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)

BACKGROUND: Ultra-hypofractionated regimens for definitive prostate cancer (PCa) radiotherapy are increasingly utilized due in part to promising safety and efficacy data complemented by greater patient convenience from a treatment course requiring fewer sessions. As such, stereotactic body radiation...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolfe, Sydney, Diven, Marshall A., Marciscano, Ariel E., Zhou, Xi Kathy, Kishan, A. U., Steinberg, M. L., Miccio, Joseph A., Camilleri, Philip, Nagar, Himanshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544147/
https://www.ncbi.nlm.nih.gov/pubmed/37777738
http://dx.doi.org/10.1186/s12885-023-11430-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544147/
https://www.ncbi.nlm.nih.gov/pubmed/37777738
http://dx.doi.org/10.1186/s12885-023-11430-z

Ejemplares similares